GREGORY KRAUSS M.D.
Prescription History 1114964921
Psychiatry & Neurology - Neurology in Baltimore, MD


Quality Rating: 74.39 out of 100 score

NPI Status: Active since June 01, 2006

Contact Information

600 N WOLFE ST
BALTIMORE, MD
ZIP 21287
Phone: (410) 955-9441

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for GREGORY KRAUSS M.D., an active Neurology specialist practicing in Baltimore, MD. Our medical registry currently tracks 26 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,430 documented patient claims. Among these therapy options, the most frequently utilized medication is Lacosamide, which accounts for 230 claims alone.


Aptiom

Generic Formulation: Eslicarbazepine AcetateSpecialty: Neurology
Provider Metrics Summary
Total Claims 19
30-Day Fills 33.0
Days Supply 981
MD State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills33.2
Peer Average Days Supply827
Conservative Utilization

This provider writes prescriptions for this formulation 34.5% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $103,585.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,451.89

State Avg Cost Per Claim

$1,442.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Eslicarbazepine is used alone or with other medications to treat a certain type of seizure disorder (focal seizures). It belongs to a class of drugs known as anticonvulsants. Eslicarbazepine may reduce the number of seizures you have.

Briviact

Generic Formulation: BrivaracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 125
30-Day Fills 181.0
Days Supply 5,308
MD State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills43.3
Peer Average Days Supply1,248
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 237.8% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $261,470.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,091.76

State Avg Cost Per Claim

$1,621.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Brivaracetam is used to treat seizures (epilepsy).

Carbamazepine Er

Generic Formulation: CarbamazepineSpecialty: Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 39.0
Days Supply 1,170
MD State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills25.9
Peer Average Days Supply736
Conservative Utilization

This provider writes prescriptions for this formulation 27.8% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,867.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$451.34

State Avg Cost Per Claim

$164.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.

Therapeutic Applications

Carbamazepine is used to prevent and control seizures. This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia). This medication works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.

Citalopram Hbr

Generic Formulation: Citalopram HydrobromideSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 13.0
Days Supply 390
MD State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills56.7
Peer Average Days Supply1,669
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.1% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $221.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.16

State Avg Cost Per Claim

$9.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A furancarbonitrile that is one of the SELECTIVE SEROTONIN REUPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.

Therapeutic Applications

Citalopram is used to treat depression. It may improve your energy level and feelings of well-being. Citalopram is known as a selective serotonin reuptake inhibitor (SSRI). This medication works by helping to restore the balance of a certain natural substance (serotonin) in the brain.

Clobazam

Generic Formulation: ClobazamSpecialty: Neurology
Provider Metrics Summary
Total Claims 135
30-Day Fills 183.4
Days Supply 5,494
MD State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills42.1
Peer Average Days Supply1,215
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 309.1% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $35,753.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$264.84

State Avg Cost Per Claim

$377.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.

Therapeutic Applications

This medication is used with other medications to help control seizures. It belongs to a class of medications called benzodiazepines, which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).

Clonazepam

Generic Formulation: ClonazepamSpecialty: Neurology
Provider Metrics Summary
Total Claims 33
30-Day Fills 37.0
Days Supply 1,025
MD State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills49.7
Peer Average Days Supply1,392
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $958.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.06

State Avg Cost Per Claim

$9.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.

Therapeutic Applications

Clonazepam is used to prevent and control seizures. This medication is known as an anticonvulsant or antiepileptic drug. It is also used to treat panic attacks. Clonazepam works by calming your brain and nerves. It belongs to a class of drugs called benzodiazepines.

Diazepam

Generic Formulation: DiazepamSpecialty: Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 18.0
Days Supply 428
MD State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.4
Peer Average Days Supply647
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,895.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$376.56

State Avg Cost Per Claim

$8.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.

Therapeutic Applications

This medication is used to treat episodes of increased seizures (such as cluster or breakthrough seizures) in people who are already taking medications to control their seizures. This product is only recommended for short-term treatment of seizure attacks. It is not for ongoing daily use to prevent seizures. Uncontrolled seizures can turn into serious (possibly fatal) seizures that do not stop (status epilepticus). This medication is not recommended for children younger than 6 months of age because of the risk of serious side effects. Diazepam works by calming the brain and nerves. It belongs to a class of drugs known as benzodiazepines.

Dilantin

Generic Formulation: Phenytoin Sodium ExtendedSpecialty: Neurology
Provider Metrics Summary
Total Claims 16
30-Day Fills 48.0
Days Supply 1,440
MD State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills15.8
Peer Average Days Supply471
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,880.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$305.03

State Avg Cost Per Claim

$81.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.

Therapeutic Applications

Phenytoin is used to prevent and control seizures (also called an anticonvulsant or antiepileptic drug). It works by reducing the spread of seizure activity in the brain.

Divalproex Sodium

Generic Formulation: Divalproex SodiumSpecialty: Neurology
Provider Metrics Summary
Total Claims 45
30-Day Fills 83.0
Days Supply 2,490
MD State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills57.7
Peer Average Days Supply1,578
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,197.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$159.94

State Avg Cost Per Claim

$41.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Divalproex Sodium Er

Generic Formulation: Divalproex SodiumSpecialty: Neurology
Provider Metrics Summary
Total Claims 33
30-Day Fills 57.3
Days Supply 1,702
MD State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills38.8
Peer Average Days Supply1,098
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,624.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$140.13

State Avg Cost Per Claim

$93.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Fycompa

Generic Formulation: PerampanelSpecialty: Neurology
Provider Metrics Summary
Total Claims 15
30-Day Fills 23.0
Days Supply 626
MD State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills20.0
Peer Average Days Supply554
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31,729.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,115.27

State Avg Cost Per Claim

$1,235.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Perampanel is used to treat certain types of seizures (including focal and generalized tonic-clonic seizures). Perampanel belongs to a class of drugs known as anticonvulsants.

Lacosamide

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 230
30-Day Fills 387.1
Days Supply 11,385
MD State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills33.8
Peer Average Days Supply839
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 751.9% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $116,101.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$504.79

State Avg Cost Per Claim

$298.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Lamictal

Generic Formulation: LamotrigineSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.2
Days Supply 364
MD State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills26.1
Peer Average Days Supply781
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $32,627.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,718.92

State Avg Cost Per Claim

$1,838.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Lamotrigine

Generic Formulation: LamotrigineSpecialty: Neurology
Provider Metrics Summary
Total Claims 77
30-Day Fills 166.5
Days Supply 4,970
MD State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills62.0
Peer Average Days Supply1,813
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 92.5% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,362.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.69

State Avg Cost Per Claim

$17.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 202
30-Day Fills 486.9
Days Supply 14,552
MD State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills67.8
Peer Average Days Supply1,910
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 348.9% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,353.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$105.71

State Avg Cost Per Claim

$44.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Lorazepam

Generic Formulation: LorazepamSpecialty: Neurology
Provider Metrics Summary
Total Claims 75
30-Day Fills 79.0
Days Supply 2,094
MD State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills42.8
Peer Average Days Supply1,109
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 97.4% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $704.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.40

State Avg Cost Per Claim

$9.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Therapeutic Applications

This medication is used to treat serious seizures that do not stop (status epilepticus). It is also used before surgeries or procedures to cause drowsiness, decrease anxiety, and cause forgetfulness about the procedure or surgery. Lorazepam belongs to a class of medications called benzodiazepines, which produce a calming effect on the brain and nerves (central nervous system). It is thought to work by increasing the effect of a certain natural chemical (GABA) in the brain.

Phenytoin Sodium Extended

Generic Formulation: Phenytoin Sodium ExtendedSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 33.0
Days Supply 990
MD State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills26.9
Peer Average Days Supply772
Conservative Utilization

This provider writes prescriptions for this formulation 38.9% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $815.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$74.18

State Avg Cost Per Claim

$38.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Phenytoin is used to prevent and control seizures (also called an anticonvulsant or antiepileptic drug). It works by reducing the spread of seizure activity in the brain.

Primidone

Generic Formulation: PrimidoneSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
MD State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,569
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.1% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $183.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.30

State Avg Cost Per Claim

$30.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.

Therapeutic Applications

This medication is used alone or with other medications to control seizures. Controlling and reducing seizures lets you do more of your normal daily activities, reduces your risk of harm when you lose consciousness, and lessens your risk for a possibly life-threatening condition of frequent, repeated seizures. Primidone belongs to a class of drugs known as barbiturate anticonvulsants. It works by controlling the abnormal electrical activity in the brain that occurs during a seizure.

Rufinamide

Generic Formulation: RufinamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 33
30-Day Fills 43.2
Days Supply 1,276
MD State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills15.6
Peer Average Days Supply464
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 153.8% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $58,659.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,777.55

State Avg Cost Per Claim

$1,351.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Rufinamide is used with other medications to prevent or control seizures (epilepsy) associated with Lennox-Gastaut syndrome (LGS). This medication is an anticonvulsant. Rufinamide is thought to work by acting on the sodium channels in the brain that carry excessive electrical charges that may cause seizures.

Topiramate

Generic Formulation: TopiramateSpecialty: Neurology
Provider Metrics Summary
Total Claims 32
30-Day Fills 42.0
Days Supply 1,260
MD State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills44.8
Peer Average Days Supply1,306
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $408.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.77

State Avg Cost Per Claim

$21.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.

Therapeutic Applications

Topiramate is used alone or with other medications to prevent and control seizures (epilepsy). This medication is also used to prevent migraine headaches and decrease how often you get them. Topiramate will not treat a migraine headache once it occurs. If you get a migraine headache, treat it as directed by your doctor (such as by taking pain medication, lying down in a dark room). Topiramate is known as an anticonvulsant or antiepileptic drug.

Valproic Acid

Generic Formulation: Valproic Acid (As Sodium Salt)Specialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 32.0
Days Supply 933
MD State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.9
Peer Average Days Supply442
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $615.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$51.29

State Avg Cost Per Claim

$40.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Valtoco

Generic Formulation: DiazepamSpecialty: Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 221
MD State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.0
Peer Average Days Supply237
Conservative Utilization

This provider writes prescriptions for this formulation 31.6% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,365.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$874.27

State Avg Cost Per Claim

$1,298.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.

Therapeutic Applications

This medication is used to treat episodes of increased seizures (such as cluster or breakthrough seizures) in people who are already taking medications to control their seizures. This product is only recommended for short-term treatment of seizure attacks. It is not for ongoing daily use to prevent seizures. Uncontrolled seizures can turn into serious (possibly fatal) seizures that do not stop (status epilepticus). This medication is not recommended for children younger than 6 months of age because of the risk of serious side effects. Diazepam works by calming the brain and nerves. It belongs to a class of drugs known as benzodiazepines.

Vigabatrin

Generic Formulation: VigabatrinSpecialty: Neurology
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 714
MD State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.5
Peer Average Days Supply375
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 108.3% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $484,007.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$19,360.29

State Avg Cost Per Claim

$18,193.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An analogue of GAMMA-AMINOBUTYRIC ACID. It is an irreversible inhibitor of 4-AMINOBUTYRATE TRANSAMINASE, the enzyme responsible for the catabolism of GAMMA-AMINOBUTYRIC ACID and is used as an anticonvulsant. (From Martindale The Extra Pharmacopoeia, 31st ed)

Therapeutic Applications

Vigabatrin is used to treat babies, one month to 2 years old who have a condition known as infantile spasms. Vigabatrin has also been used in combination with other medications to treat seizure disorders (epilepsy). Vigabatrin decreases the number of seizures in adults and children who have not been able to control their seizures with other treatment. Vigabatrin is an anticonvulsant. It is thought to work by stopping the breakdown of a natural calming substance (GABA) in the brain.

Vimpat

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 38
30-Day Fills 44.0
Days Supply 1,316
MD State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills31.4
Peer Average Days Supply785
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 46.2% more claims than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $46,380.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,220.55

State Avg Cost Per Claim

$1,173.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Xcopri

Generic Formulation: CenobamateSpecialty: Neurology
Provider Metrics Summary
Total Claims 149
30-Day Fills 241.2
Days Supply 7,144
MD State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills62.8
Peer Average Days Supply1,807
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 175.9% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $405,437.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,721.06

State Avg Cost Per Claim

$1,434.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of seizure disorder (partial onset). It is not known exactly how it works, but it may affect the action of some nerves that cause seizures.

Zonisamide

Generic Formulation: ZonisamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 51
30-Day Fills 92.8
Days Supply 2,758
MD State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills44.1
Peer Average Days Supply1,273
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 88.9% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,331.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$65.31

State Avg Cost Per Claim

$45.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Therapeutic Applications

Zonisamide is used with other medications to prevent and control seizures (epilepsy). Zonisamide is a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It is unknown how zonisamide works to prevent seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like GREGORY KRAUSS M.D. provides transparency into local medical care patterns within Baltimore, MD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.